Novel Mixed-Type Inhibitors of Protein Tyrosine Phosphatase 1B. Kinetic and Computational Studies

Marie Jazmín Sarabia-Sánchez1, Pedro Josué Trejo-Soto2, José Miguel Velázquez-López3

  • 1Facultad de Medicina y Nutrición, Universidad Juárez del Estado de Durango, Av. Universidad y Fanny Anitúa S/N, Durango, Durango C.P. 34000, Mexico. marie_sarabia@hotmail.com.

Insights

Researchers identified three potent compounds that inhibit protein tyrosine phosphatase 1B (PTP1B), a key target for developing new type 2 diabetes treatments. These PTP1B inhibitors show promise for future antidiabetic drug design.

Area of Science:

  • Biochemistry
  • Pharmacology
  • Medicinal Chemistry

Background:

  • Type 2 diabetes affects over 415 million people globally, exceeding projections.
  • Insulin resistance and defective insulin secretion characterize type 2 diabetes.
  • Protein tyrosine phosphatase 1B (PTP1B) is a validated target for enhancing insulin action.

Purpose of the Study:

  • To screen a chemical library for novel PTP1B inhibitors.
  • To identify lead compounds for the development of new antidiabetic drugs.

Main Methods:

  • Screening of 250 compounds for PTP1B inhibition.
  • Characterization of the most potent inhibitors, including kinetic analysis (Ki values).
  • Computational studies: docking and molecular dynamics simulations.

Main Results:

  • Ten compounds inhibited PTP1B activity by over 50%.
  • Three potent inhibitors were identified with Ki values of 5.2, 4.2, and 41.3 µM.
  • Inhibitors interacted with residues at PTP1B's unique secondary phosphate-binding site.

Conclusions:

  • The identified compounds are promising hits for designing selective PTP1B inhibitors.
  • These findings support the development of novel antidiabetic therapeutics targeting PTP1B.